In an effort to improve the quality of care and delivery costs, seven preferred provider organizations have joined Blue Cross Blue Shield of Michigan’s “Blueprint for Affordability” payment model. Read More
Medicare beneficiaries with end-stage renal disease (ESRD) are experiencing an increase in efficient care thanks to the Combined force of the Comprehensive ESRD Care (CEC) Model and the recent Executive… Read More
The FDA has solidified its stance of focusing on high-risk digital health tools. Read about the wider scope of the FDA’s released guidance on health care technology. Read More
Learn about some of the perspectives and rationales that families have adopted when dealing with genetic consultations for at-risk children. Read More
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.